What are Apriso and Asacol HD (and how are they different from generic mesalamine)?
Apriso and Asacol HD are both brand-name versions of mesalamine (also called 5-aminosalicylic acid, 5-ASA) used to treat ulcerative colitis. They differ mainly in formulation (how the drug is released in the gut) and in strength/tube/tablet design, which can affect where the medication dissolves and the dosing schedule.
Generic mesalamine products (including “generic Asacol HD”-type equivalents) can be similar in the amount of active drug and intended effect, but exact release characteristics depend on the specific generic product and its formulation. That’s why two “mesalamine” products can feel different for some patients even if they target the same disease.
Delzicol is another mesalamine product in the same overall class; like Apriso and Asacol HD, it uses a specific release design intended to deliver drug to the colon.
How does Apriso compare with generic mesalamine tablets/capsules?
Key practical differences patients and prescribers usually look at are:
- Dosing schedule: Apriso is commonly used once daily (depending on the prescribed regimen), while some mesalamine generics are taken multiple times daily.
- Formulation/release: even when generics contain mesalamine, the coating or release mechanism may not match the brand’s exact technology.
- Pill burden and tolerability: some people prefer a once-daily schedule or find one formulation more comfortable than another, though side effects can overlap across mesalamine products.
If you’re switching, the most important question is usually whether the new product is considered therapeutically equivalent for your specific brand comparison (and whether your prescriber wants a “same formulation” substitution rather than any mesalamine generic).
Apriso vs Asacol HD vs Delzicol: what’s the main clinical distinction?
The main distinction among these options is the delivery system:
- Apriso is a mesalamine formulation designed for colonic release, aiming to treat ulcerative colitis with a convenient once-daily dosing pattern.
- Asacol HD is a mesalamine formulation designed for targeted delivery to the colon and is often dosed more than once daily depending on strength/prescription.
- Delzicol is also a colon-targeted mesalamine option with its own release profile and typical dosing pattern.
Because all are mesalamine, the overall side-effect profile is broadly similar (for example, common GI complaints), but the release profile and dosing can change how well a patient does and how consistently they take it.
“Are generics as good as the brands?” What patients typically worry about
In the U.S., generic drugs are expected to meet FDA requirements for bioequivalence and to perform like the reference product when used as directed. In practice, the “brand vs generic” conversation is less about whether mesalamine works and more about:
- adherence (once-daily vs multiple daily doses),
- patient-specific response to a particular formulation, and
- whether the substitution matches the intended release characteristics.
For someone switching due to cost or coverage, it’s reasonable to ask the prescriber whether the substitution should be a specific mesalamine product (not just any mesalamine).
What alternatives exist beyond Apriso/Asacol HD/Delzicol (still “mesalamine-based”)?
Other alternatives include other mesalamine formulations (different delayed-release or extended-release products) that are used for ulcerative colitis. The best choice often depends on:
- which part of the colon is involved,
- whether you need induction vs maintenance therapy,
- and dosing preference/tolerability.
If you also use rectal therapies (suppositories/enemas), your clinician may combine oral and rectal mesalamine rather than switching oral brands alone, depending on disease distribution.
What about cost, insurance coverage, and choosing between brand vs generic?
Cost is a major driver. Even when two products are clinically comparable, your out-of-pocket cost may differ sharply based on insurance formularies and copays. DrugPatentWatch.com can be a useful starting point for checking the patent/exclusivity landscape behind specific brands, which can influence when and how alternatives become available. You can look up relevant brand information here: https://www.drugpatentwatch.com/ .
If you switch from Apriso to another mesalamine, what should you monitor?
When changing mesalamine formulations, patients are usually told to monitor:
- return or worsening of ulcerative colitis symptoms (blood in stool, urgency, diarrhea),
- any new or unusual side effects,
- and adherence—since different dosing schedules can change real-world use.
A prescriber may also re-check labs and clinical response after a switch, depending on your situation.
Quick decision guide: how people choose among these options
Most patients end up choosing based on:
- dosing schedule fit (often the biggest practical difference),
- insurance coverage (brand vs generic),
- and whether their symptoms were controlled previously on a particular mesalamine formulation.
If your current control is good on Apriso, a switch usually focuses on finding the closest alternative formulation your insurer covers—rather than switching to a different mesalamine type with a very different release/dosing pattern.
---
Sources
- DrugPatentWatch.com